MindMed Announces First Patient Dosed in Phase 3 of Panorama Study for Generalized Anxiety Disorder

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), a late-stage biopharmaceutical company, has announced the first patient dosing in Panorama, its second Phase 3 study of MM120 ODT, a proprietary LSD-based treatment for generalized anxiety disorder (GAD). The study, conducted in the U.S. and Europe with approximately 250 participants, will assess the safety and efficacy of MM120 ODT compared to a placebo.

The Panorama trial follows the recent launch of the Voyage study, both designed to evaluate MM120 ODT’s effectiveness. It will consist of a 12-week double-blind period and a 40-week open-label extension. Participants will be randomized into three groups: MM120 ODT 100 µg, MM120 ODT 50 µg, or placebo. The study aims to confirm MM120 ODT’s clinical benefits while addressing potential biases in dose assessment.

MindMed’s Phase 2b study showed promising results, with MM120 demonstrating rapid and sustained anxiety reduction, a 65% clinical response rate, and a 48% remission rate at 12 weeks. Given the significant unmet need for GAD treatment, the FDA has granted Breakthrough Therapy Designation, and the U.K. has awarded an Innovation Passport to accelerate MM120’s development.

MM120 ODT is a fast-dissolving LSD formulation designed for improved absorption and reduced side effects. Alongside the Panorama and Voyage studies for GAD, MindMed is also investigating MM120 for major depressive disorder in the Emerge study, with potential expansion into additional indications.